Please login to the form below

Not currently logged in
Email:
Password:

Reata

This page shows the latest Reata news and features for those working in and with pharma, biotech and healthcare.

Abbott stops kidney disease drug trial on safety concerns

Abbott stops kidney disease drug trial on safety concerns

Abbott Laboratories suffered a late-stage pipeline blow yesterday after partner Reata Pharmaceuticals was forced to halt all trials of a kidney disease drug on safety concerns. ... All other clinical trials of the drug have also been suspended and Reata

Latest news

  • Abbott pays $110m for investigational kidney injury drug

    Bardoxolone is being developed in partnership with Reata Pharmaceuticals, while atrasentan was discovered in-house.

  • Abbott cuts 700 US jobs as it prepares for a major restructure

    Excluding these charges, as well as other one-off items, such as costs related to the company's Reata and Biotest collaborations, profits would have risen by 12.8 per cent,

  • Abbott agrees $400m chronic disease deal with Reata

    Abbott agrees $400m chronic disease deal with Reata. Will collaborate on oral treatments for pulmonary and central nervous system disorders and in immunology. ... For these conditions, Abbott will take 70 per cent of costs and profits, while Reata will

  • Regional plans

    A similar rationale applies to the deal between Abbott and Reata where Abbott will be providing the global marketing capability outside the US. ... Platform. 480. PregLem/Richter. Corporate acquisition. 461. Reata/Abbott. Bardoxolone for chronic kidney

  • Abbott signs kidney drug deal

    Abbott signs kidney drug deal. Abbott has licensed rights from Reata Pharmaceuticals to develop and commercialise a phase II drug for chronic kidney disease. ... Abbott has licensed rights from Reata Pharmaceuticals to develop and commercialise a phase

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics